Self‐reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens

Background  Moderate/severe psoriasis combined with psoriatic arthritis (PsA) impairs health‐related quality of life (QoL). Etanercept, a fully human tumour necrosis factor‐α receptor fusion protein, is approved for treatment of both diseases.

[1]  J. Ortonne,et al.  Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial , 2010, BMJ : British Medical Journal.

[2]  P. V. D. van de Kerkhof,et al.  Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis , 2009, Dermatology.

[3]  W. Gulliver,et al.  Psoriasis Comorbidities , 2009, Journal of cutaneous medicine and surgery.

[4]  J. Ortonne,et al.  Improvements in patient‐reported outcomes in moderate‐to‐severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  A. Gottlieb,et al.  Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial , 2009, The Lancet.

[6]  A. Gottlieb,et al.  Treatment recommendations for psoriatic arthritis , 2008, Annals of the rheumatic diseases.

[7]  C. Kneitz,et al.  Psoriatic arthritis: therapeutic principles. , 2008, Clinics in dermatology.

[8]  F. Breedveld,et al.  Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial , 2008, The Lancet.

[9]  D. Symmons,et al.  Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. , 2008, The Journal of rheumatology.

[10]  T. Kvien,et al.  Measuring disability and quality of life in established rheumatoid arthritis. , 2007, Best practice & research. Clinical rheumatology.

[11]  P. V. van Riel,et al.  Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial , 2007, Annals of the rheumatic diseases.

[12]  D. Gladman,et al.  Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial , 2006, Annals of the rheumatic diseases.

[13]  P. Mease.  Management of psoriatic arthritis: The therapeutic interface between rheumatology and dermatology , 2006, Current rheumatology reports.

[14]  R. Shikiar,et al.  The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study , 2006, Health and quality of life outcomes.

[15]  D. Gladman,et al.  Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis , 2005, Annals of the rheumatic diseases.

[16]  J. Sharp,et al.  Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. , 2004, Arthritis and rheumatism.

[17]  R. Zachariae,et al.  Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. , 2002, Acta dermato-venereologica.

[18]  T. T. Haug,et al.  The validity of the Hospital Anxiety and Depression Scale. An updated literature review. , 2002, Journal of psychosomatic research.

[19]  P. Helliwell,et al.  Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. , 2001, The Journal of rheumatology.

[20]  D. Gladman,et al.  Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[21]  M. Lebwohl,et al.  The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. , 2001, Archives of dermatology.

[22]  M. Johannesson,et al.  Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. , 2000, Acta dermato-venereologica.

[23]  J. Ware,et al.  Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[24]  M. Gupta,et al.  Psoriasis and sex: a study of moderately to severely affected patients , 1997, International journal of dermatology.

[25]  D. Gladman,et al.  Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. , 1997, The Journal of rheumatology.

[26]  J. Ormel,et al.  A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects , 1997, Psychological Medicine.

[27]  M. Drummond,et al.  Statistical Versus Quantitative Significance in the Socioeconomic Evaluation of Medicines , 1994, PharmacoEconomics.

[28]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[29]  D. Gladman,et al.  Psoriatic arthritis (PSA)--an analysis of 220 patients. , 1987, The Quarterly journal of medicine.

[30]  B. Janssen,et al.  Population Norms for the EQ-5D , 2014 .

[31]  D. Lubeck,et al.  Patient-reported outcomes and their role in the assessment of rheumatoid arthritis , 2012, PharmacoEconomics.

[32]  J. Weinberg.  Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial , 2010 .

[33]  J. Fries,et al.  The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. , 2003, The Journal of rheumatology.

[34]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[35]  A. Kasuya.  EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[36]  W. Eyler,et al.  PSORIATIC ARTHRITIS. , 1965, Henry Ford Hospital medical bulletin.

[37]  E. G. Lantarel,et al.  Treatment goals in psoriasis , 2022 .